A Palliative Approach to Management of Peritoneal Carcinomatosis and Malignant Ascites.
Bleicher J, Lambert LA.
Surg Oncol Clin N Am. 2021 Jul;30(3):475-490. doi: 10.1016/j.soc.2021.02.004.
Viscosity and Characteristics of Malignant Ascites.
Maehara K, Hijioka S, Takeshita K, Kanno A, Okusaka T.
Anticancer Res. 2024 Feb;44(2):533-542. doi: 10.21873/anticanres.16841.
Malignancy of Malignant Ascites: A Comprehensive Review of Interplay between Biochemical Variables, Tumor Microenvironment and Growth Factors.
Jacob R, A S, Abdul Razack N, Prabhuswamimath SC.
Asian Pac J Cancer Prev. 2024 Oct 1;25(10):3413-3420. doi: 10.31557/APJCP.2024.25.10.3413.
Malignant ascites: past, present, and future.
Adam RA, Adam YG.
J Am Coll Surg. 2004 Jun;198(6):999-1011. doi: 10.1016/j.jamcollsurg.2004.01.035.
Malignant ascites as an immune organ and implications for cancer immunotherapy.
Basov DD, Dorman MJ, Burton KA, Metropulos AE, Munshi HG, Principe DR.
Cancer Lett. 2026 Jul 28;651:218533. doi: 10.1016/j.canlet.2026.218533. Epub 2026 Apr 22.
Treatment of malignant ascites.
Chung M, Kozuch P.
Curr Treat Options Oncol. 2008 Jun;9(2-3):215-33. doi: 10.1007/s11864-008-0068-y. Epub 2008 Sep 6.
Metabolome Profiling of Malignant Ascites Identifies Candidate Metabolic Biomarkers of Hepatocellular Carcinoma.
Wang W, Wu Y, Zhang Q, Cui P.
Curr Med Chem. 2024;31(13):1769-1780. doi: 10.2174/0929867330666230324153552.
Management of drainage for malignant ascites in gynaecological cancer.
Keen A, Fitzgerald D, Bryant A, Dickinson HO.
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007794. doi: 10.1002/14651858.CD007794.pub2.
Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015.
Krugmann J, Schwarz CL, Melcher B, Sterlacci W, Ozalinskaite A, Lermann J, Agaimy A, Vieth M.
Arch Gynecol Obstet. 2019 Feb;299(2):515-523. doi: 10.1007/s00404-018-4952-9. Epub 2018 Nov 10.
PD-L1(+) neutrophils induced NETs in malignant ascites is a potential biomarker in HCC.
Sun X, Gui Y, Yang T, Chen L, Zhang Y, Yan L, Chen W, Wang B.
Cancer Immunol Immunother. 2024 Oct 3;73(12):254. doi: 10.1007/s00262-024-03833-z.
